Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV

Executive Summary

Capsid assembly modulation, small-interfering RNA, a TLR7 agonist and a DNA-based vaccine are some of the components of the pharma’s strategy for bringing about significant advancement in hepatitis B therapy.

You may also be interested in...



Antios Says Its Novel Hepatitis B Mechanism Can Help Toward Functional Cure

First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.

GSK Opts In On Ionis’ Antisense Candidates For Hep B

The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.

J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B

The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC097671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel